Browse Primary Care/Hospitalist Articles by Topic

Gay, lesbian, and bisexual youth grouped, show increased risk for unintended pregnancy

The United States has seen significant advances in rights for lesbian and gay populations this summer, with the Supreme Court’s decision affirming same-sex marriage nationwide. As we celebrate this victory, however, we remain aware of the many challenges still facing lesbian, gay, and bisexual populations, including health disparities. Many such disparities affect youth, especially in the areas of sexual and reproductive health.

Study: Obese teens less likely to use contraception

A study of nearly 1,000 Michigan teens found that sexually active obese adolescents were significantly less likely to use contraception than normal weight peers.

Long-acting reversible contraceptives used by few women after delivery

Researchers recently looked at national data to investigate women’s patterns of contraceptive use after delivery and the association between method use and risk of pregnancy within 18 months.

What are the options available for medication prior to IUD placement?

While the American College of Obstetricians and Gynecologists recommends taking over-the-counter pain medication prior to intrauterine device insertion, no specific drug is recommended.

Single-size Caya diaphragm is available by prescription in U.S.

The Caya single-size diaphragm, the first new cervical barrier method to enter the market in more than 10 years, is available by prescription from U.S. healthcare providers.

Counseling on LARC methods cuts unintended pregnancy rates

Training clinicians to inform women that different birth control methods have very different levels of effectiveness proved key in cutting the number of unintended pregnancies among young women seeking family planning services, data suggests from a new national study from the Bixby Center for Global and Reproductive Health at the University of California, San Francisco.

Clinical Brief

Briefs

Dulaglutide Injection (Trulicity™)

The FDA has approved a third long-acting, once-weekly, glucagon-like peptide (GLP-1) receptor agonist for the treatment of type 2 diabetes mellitus, joining exenetide ER and albiglutide. Dulaglutide is made up of two identical human-based GLP-1 analogs linked to a modified human IgG4 Fc fragment. This makes the molecule resistant to degradation by DPP-4, slows absorption, reduces renal clearance, and extends the elimination half-life to approximately 5 days. Dulaglutide is marketed by Eli Lilly as Trulicity.

Angiotensin Receptor Blockers for Hypertension

Angiotensin receptor blockers (ARBs) are often used as first-line therapy for the treatment of systemic hypertension because of their perceived efficacy and relatively low incidence of adverse effects.

Colchicine for Recurrent Pericarditis

Although colchicine has been shown to be effective for the treatment of acute pericarditis and first recurrences, little information exists about its use in patients with multiple recurrences.